Browsing Tag
Obesity Drugs
17 posts
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)
Veru Inc. launches the Phase 2b PLATEAU trial combining enobosarm with semaglutide. Discover what this could mean for the $100B obesity drug market.
Verdiva Bio advances VRB-101 into late-stage positioning with fully enrolled Phase 2b obesity study
Find out why Verdiva Bio’s Phase 2b enrollment milestone could determine whether once-weekly oral GLP-1 drugs can truly challenge injectables.
Why Eli Lilly’s Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepbound’s market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
AbbVie commits $380m to expand US drug manufacturing as supply chain control becomes strategic
AbbVie is investing $380 million to expand US drug manufacturing. Find out how this reshapes supply chains, margins, and long-term pharma strategy.
Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes
Eli Lilly and Company is ramping inventory ahead of a key FDA decision on its oral weight loss pill. Find out what this signals for obesity drugs and investors.
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.